CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 130 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2020. The put-call ratio across all filers is 0.95 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,007,160 | +3.5% | 145,609 | +27.6% | 0.01% | +7.7% |
Q2 2023 | $3,872,431 | -4.4% | 114,130 | +1.4% | 0.01% | -7.1% |
Q1 2023 | $4,049,909 | -19.5% | 112,560 | -0.2% | 0.01% | -22.2% |
Q4 2022 | $5,028,343 | -43.8% | 112,819 | -64.6% | 0.02% | 0.0% |
Q3 2022 | $8,951,646 | +29.9% | 318,438 | +24.6% | 0.02% | +38.5% |
Q2 2022 | $6,891,919 | -34.7% | 255,632 | -17.5% | 0.01% | -13.3% |
Q1 2022 | $10,553,677 | +71.9% | 309,846 | +95.0% | 0.02% | -6.2% |
Q4 2021 | $6,141,000 | -30.2% | 158,922 | -2.5% | 0.02% | -36.0% |
Q3 2021 | $8,800,000 | -42.5% | 162,983 | -64.4% | 0.02% | +13.6% |
Q2 2021 | $15,312,000 | +149.6% | 457,902 | +53.8% | 0.02% | +15.8% |
Q1 2021 | $6,134,000 | +3233.7% | 297,783 | +2736.0% | 0.02% | +1800.0% |
Q4 2020 | $184,000 | – | 10,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 2,600,000 | $88,218,000 | 12.13% |
Octagon Capital Advisors LP | 759,898 | $25,783,339 | 3.59% |
TSP Capital Management Group, LLC | 251,895 | $8,546,800 | 3.08% |
ACUTA CAPITAL PARTNERS, LLC | 122,343 | $4,151,098 | 2.81% |
5AM Venture Management, LLC | 310,270 | $10,527,461 | 2.62% |
COMMODORE CAPITAL LP | 631,665 | $21,432,393 | 2.41% |
RTW INVESTMENTS, LP | 3,463,201 | $117,506,410 | 2.24% |
Eversept Partners, LP | 785,740 | $26,660,158 | 2.23% |
Redmile Group, LLC | 1,696,004 | $57,545,416 | 2.21% |
Affinity Asset Advisors, LLC | 87,031 | $2,952,962 | 1.03% |